Skip to content
  • Home
  • History
    • Introduction
    • The Aspirin Story
    • Timeline
    • Chemistry
  • Advisory Board
  • Awards
  • Conferences
  • Scientific Information
    • Guidelines
    • Disease Prevention
    • Aspirin Summaries
    • Aspirin Matters
  • News
  • Contact
Menu
  • Home
  • History
    • Introduction
    • The Aspirin Story
    • Timeline
    • Chemistry
  • Advisory Board
  • Awards
  • Conferences
  • Scientific Information
    • Guidelines
    • Disease Prevention
    • Aspirin Summaries
    • Aspirin Matters
  • News
  • Contact
Search
Close

Conferences

Our biennial conference is a great opportunity to hear from leading biomedical researchers across a range of specialties.  By coming together discuss the latest international data, we can enhance understanding, build stronger networks and inspire new ideas.

  • 2022 Scientific Conference
  • – Conference Speakers
  • 2021 Scientific Conference
  • – Conference Speakers
  • – Conference Videos
  • 2019 Scientific Conference
  • – Conference Speakers
  • – Conference Videos
  • 2018 Scientific Conference
  • – Conference Speakers
  • 2017 : ASPIRIN: 120 Years of Innovation
  • – Conference Speakers
  • 2015 : ASPIRIN In The 21ST Century
  • – Conference Speakers
  • – Conference Videos
  • 2022 Scientific Conference
  • – Conference Speakers
  • 2021 Scientific Conference
  • – Conference Speakers
  • – Conference Videos
  • 2019 Scientific Conference
  • – Conference Speakers
  • – Conference Videos
  • 2018 Scientific Conference
  • – Conference Speakers
  • 2017 : ASPIRIN: 120 Years of Innovation
  • – Conference Speakers
  • 2015 : ASPIRIN In The 21ST Century
  • – Conference Speakers
  • – Conference Videos
Menu
  • 2022 Scientific Conference
  • – Conference Speakers
  • 2021 Scientific Conference
  • – Conference Speakers
  • – Conference Videos
  • 2019 Scientific Conference
  • – Conference Speakers
  • – Conference Videos
  • 2018 Scientific Conference
  • – Conference Speakers
  • 2017 : ASPIRIN: 120 Years of Innovation
  • – Conference Speakers
  • 2015 : ASPIRIN In The 21ST Century
  • – Conference Speakers
  • – Conference Videos

2017 Conference Speakers

The International Aspirin Foundation 2017: ASPIRIN: 120 Years of Innovation attracted worldwide speakers.

Rothwell

Prof Peter M Rothwell

Peter M Rothwell

Professor

Action Research Professor of Neurology, Director of the Stroke Prevention Research Unit, University of Oxford

Peter Rothwell is the Action Research Professor of Neurology in the Nuffield Department of Clinical Neuroscience, University of Oxford. He qualified in medicine at the University of Edinburgh in 1987 and after completing his early postgraduate clinical training he moved to Oxford as Clinical Lecturer in Neurology in 1996. He was awarded an MRC Senior Clinical Fellowship in 1999 and set up the Stroke Prevention Research Unit in 2000, which now employs over 40 research staff.

He was awarded Professor of Clinical Neurology in 2004 and was elected a fellow of the Academy of Medical Sciences in 2008, a National Institute of Health Research Senior Investigator in 2009 and a Wellcome Trust Senior Investigator in 2011. He has published over 400 scientific papers and several books. His research interests include primary and secondary prevention of stroke, the effects of blood pressure on the brain, and the risks and benefits of aspirin.

He is clinically active, working as a Consultant Neurologist for the Oxford University Hospitals Trust and contributing to clinical services for general neurology and stroke prevention. He has received several awards for other areas of his research, including the Inaugural British Medical Journal Award for Outstanding Contribution to Clinical Research (2009), the Foulkes Foundation Medal, Academy of Medical Sciences (2009), the World Stroke Organisation President’s Biennial Award for Outstanding Research (2010), a Wellcome Trust Senior Investigator Award (2011), the Kinmonth Medal, Royal College of Surgeons (2012), the Queen’s Anniversary Prize for Higher and Further Education (2013) and The Inaugural International Aspirin Foundation Senior Scientific Award (2014).

Dong Zhao

Dr Dong Zhao

Dong Zhao

Doctor

Dong Zhao, chief physician, PhD, doctoral tutor, deputy director of Beijing Institute of heart lung and blood vessel disease, director of epidemiology research department, An Zhen Hospital, Beijing, China

Experts Committee member for: Disease Control of the Ministry of Health, National Cardiovascular Center, Chinese Society of Cardiology, Cardiovascular Disease branch of Chinese Physicians’ Association, International Society of Atherosclerosis.

Vice chairman for: Chinese Society for prevention of chronic diseases, Cardiovascular Disease Branch of Chinese Female Physicians’ Association.

Involved in Chinese Guidelines and international guidelines update: Prevention and Treatment of Hypertension, Prevention and Treatment of Dyslipidemia, Guideline for Cardiovascular Disease Prevention. World Health Organization Guidelines for cardiovascular disease prevention and American Heart Association guidelines of Cardiovascular Disease Prevention in women. Published more than 200 hundreds papers in professional journals.

Award: the first prize of Scientific Progress Award of the Ministry of Education in 2011, the Chinese Medical Prize in 2013, the second prize of Scientific and Technological Progress in Beijing City in 2005.

Yongjun Wang

Professor Yongjun Wang

Yongjun Wang

Professor

Professor Yongjun Wang, chief physician, professor, doctoral tutor, vice president of Beijing Tiantan Hospital affiliated to Capital Medical University

Executive vice president or Chairmen: Chinese Stroke Association, Chinese Society of Neurology, Stroke Prevention and Control Society, Chinese Preventive Medicine Association.

Editor of journals: Chinese Journal of Stroke, Chinese Journal of Internal Medicine, CNS Neuroscience & Therapeutics, Stroke, a member of the World Stroke Organization.

Research interests: cerebrovascular disease clinical and applied basic research work. He published CHANCE study which was adopted by AHA/ASA 2014 “Guidelines for the Prevention of Stroke in Patients With Stroke and TIA”, and “2014 Chinese Guidelines for the Secondary Prevention of Ischemic Stroke and TIA”. He has published more than 100 SCI papers as the first author or corresponding author.

Award: the first prize of Beijing Science and Technology Award, the first prize of Science and Technology of the Chinese Preventive Medicine Association, the first prize of Science and Technology Progress Award of Ministry of Education, the outstanding achievement award of “2014 WuXi PharmaTech Life Chemistry Research Award”. “Beijing scholar” in 2015.

John Burn

Professor Sir John Burn

Sir John Burn

Professor

Professor Sir John Burn obtained an MD with distinction, a first class honours degree in human genetics from Newcastle University, where he has been Professor of Clinical Genetics since 1991 and a consultant specialist since 1984. He led the regional NHS Genetics Service for 20 years and helped to create the Centre for Life which houses an education and science centre alongside the Institute of Genetic Medicine and Northgene Ltd, the identity testing company he launched in 1995. He chairs DNA device company QuantuMDx. He was knighted in 2010, chosen as one of the first 20 ‘local heroes’ to have a brass plaque on Newcastle Quayside in 2014. He received the Living North award in 2015 for services to the North East 2000 – 2015. He is also a non-Executive Director of NHS England.

Gaziano

Prof Mike Gaziano

Mike Gaziano

Professor

I am a chronic disease epidemiologist. I have a particular interest in the roles that individual lifestyle choices (diet, exercise, smoking), metabolic factors (obesity, high cholesterol, and hypertension), and biochemical and genetic markers play on the risk of coronary artery disease and stroke. Also of interest is the impact that vascular disease has on other organ systems, including cognitive dysfunction and renal disease.

Recently, I have initiated a number of research projects to investigate the diverse nature of atherosclerosis and I serve as the director of the Geriatric Research and Education Center (GRECC) at the VA Boston Healthcare System.

Chan

Dr Andrew T Chan

Andrew T Chan

Doctor

Dr Andrew T Chan is an Associate Professor of Medicine at Harvard Medical School and an attending gastroenterologist at Massachusetts General Hospital (MGH) with a clinical specialty in familial gastrointestinal cancer syndromes. He is Chief of the Clinical and Translational Epidemiology Unit and the Program Director for gastroenterology training at MGH. His research focus is in clinical and translational epidemiology of colorectal cancer, with a focus on chemoprevention with aspirin.

Chris Hawkey

Prof Chris Hawkey

Chris Hawkey

Professor

Christopher Hawkey is Professor of Gastroenterology at the Nottingham Digestive Diseases Centre. His main interests are in the field of non-steroid anti-inflammatory drugs and inflammatory bowel disease. In both areas his approach is to try to identify targets in small exploratory studies and then evaluate them in large and/or outcomes studies.

Chia

Dr John Chia

John Chia

Doctor

Dr John WK Chia is Senior Consultant, at the National Cancer Centre Singapore. Graduating from the National University of Singapore, he later obtained his Membership of the Royal College of Physicians in Edinburgh in 2002 and upon completing his Oncology Boards, he underwent fellowship training in “Immunotherapy for Solid Tumors” – with Malcom Brenner at the Centre for Cell and Gene Therapy, Baylor College, Houston, for the development of cancer vaccines and adoptive T-cell therapy. He undertook a second clinical fellowship in with Prof Stan Kaye at The Royal Marsden Hospital London from 2011 to 2012 in the advanced management of Gynecological cancers.

Dr Chia is active in clinical trial research; and has developed and/or led numerous clinical trial studies– including immune check-point inhibitors, cancer vaccines, adoptive T cell therapy, and small molecule targets for cancer and he holds scientific research grants both locally and internationally.

Langley

Dr Ruth Langley

Ruth Langley

Doctor

Dr Ruth Langley is based at the UK Medical Research Council Clinical Trials Unit at University College London where she jointly leads the Cancer Group; and has a clinical consultant post at the Brighton and Sussex University Hospital.

She has a particular interest in gastro-oesophageal malignancy and has co-ordinated a series of trials and associated translational studies, and has led the investigation of the use of transdermal oestrogen in the treatment of prostate cancer.

Dr Langley is the Chief Investigator of an international trial (Add-Aspirin) designed to assess the effect of aspirin as an additional adjuvant agent in several common solid tumours.

Valerie O'donnell

Dr Valerie O'Donnell

Valerie O'Donnell

Doctor

Dr Valerie O’Donnell is Professor of Biochemistry and Co-Director of the Systems Immunity Research Institute, Cardiff University. She uses mass spectrometry to uncover new lipids involved in inflammatory processes, and is funded by British Heart Foundation and Welcome Trust. She is an ERC Advanced Investigator. Following a PhD in Bristol, studying enzymology of NADPH oxidase in neutrophils, she completed post doctoral fellowships in Bern, Switzerland and with Bruce Freeman and Victor Darley-Usmar at University of Alabama at Birmingham. She moved to Cardiff in 1999 on a Wellcome Trust CDA Fellowship. Her research group studies vascular inflammation, applying informatics, machine learning and statistics to global analysis and discovery lipidomics projects which aim to uncover new mechanisms of lipid signaling in disease.

Biancarocca

Dr Bianca Rocca

Bianca Rocca

Doctor

Bianca Rocca, MD, PhD is Professor of Pharmacology at the Catholic University School of Medicine in Rome (Italy). Prof. Rocca trained as Postdoctoral Fellow at the Center for Experimental Therapeutics, University Pennsylvania of Philadelphia (USA) with Prof. Garret A. FitzGerald. Prof. Bianca Rocca is member of the Editorial Board of the ‘European Heart Journal-Cardiovascular Pharmacology’, listed in the Top Italian Scientists, she has co-authored over 100 articles with over 5500 citations in peer-reviewed journals, including: Nature Medicine, Science, Blood, Circulation, Journal of Clinical Investigation, PNAS (USA), Annals of Internal Medicine, ATVB, Nature Clinical Practice in Cardiovascular Medicine, JACC, European Heart Journal, Diabetes. She has been appointed by the European Society of Cardiology as the Chairperson of the Working Group on Thrombosis (2016-2018). Her H-index is 36. Main scientific topics of interest are: antiplatelet drugs, eicosanoids, primary haemostasis, platelets, non-steroidal anti-inflammatory drugs, cardiovascular diseases.

Connect with us

Sign up to be part of the aspirin community and be the first to receive latest information.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Have something to say about aspirin?

Contact Us Here
Footer Logo
  • Terms & Conditions
  • Branding Guidelines
  • Privacy
  • Cookie Policy
  • Disclaimer
  • Terms & Conditions
  • Branding Guidelines
  • Privacy
  • Cookie Policy
  • Disclaimer
TwitterLinkedin

Copyright © 2020 Aspirin Foundation

Website by mtc.

Have something to say about aspirin?

Please fill in the form below and we will contact you with further information.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Djp

Daniel José Piñeiro

ASSOCIATE
Name
Daniel José Piñeiro
Academic Affiliations:
Full Professor of Medicine, Universidad de Buenos Aires, Argentina Trustee, Board of Trustees, American College of Cardiology
Professional Setting:
My academic experience includes more than 40 years as a practicing medical doctor, teacher, and researcher. I have fulfilled these appointments in settings of vital social engagement and impact, most notably at the Hospital de Clínicas “José de San Martín” of the Universidad de Buenos Aires, a public hospital with high academic recognition. Additionally, I currently hold the position of Full Professor of Medicine at that same University.
Academic Activities:
  • International Meetings Participations: 180
  • Books-Editor: 1
  • Books Chapters: 39
  • Refereed Full Articles: 118 (listed in Pubmed: 29)
  • Refereed Abstracts: 221
  • Editorial Boards: 10
Profesional Associations:
  • 2005 President, Sociedad Argentina de Cardiología.
  • 2011-2013 President, Inter-American Society of Cardiology.
  • 2011-2013 Member (ex-officio), Board of Directors, World Heart Federation
  • 2017-2018 Member (at large), Board of Directors, World Heart Federation
  • 2018-2021 Trustee, Board of Trustees, American College of Cardiology
Return to Scientific Advisory Board
Chia

John Chia

Name
John Chia MBBS (Spore), MRCP (UK), FAMS (Spore)
Academic Affiliations:

Adjunct Associate Professor DUKE-NUS Graduate Medical School,
Consultant Oncologist Curie Oncology Singapore,
Visiting Consultant National Cancer Centre Singapore.

Discipline:

Medical Oncology

Scientific Interests:
  • Aspirin as adjuvant therapy in established cancers
  • Adoptive T cell therapy and Dendritic cell vaccines in the treatment of solid tumors
  • Clinical Trial Design and Management
Declaration of Conflicts of Interest:

In the past 3 years, I have received consultant fees from Tessa Therapeutics, Aslan Pharmaceuticals, Novartis, and AstraZeneca.

I received grant support for investigator-initiated research from:

  • National Medical Research Council Singapore
  • Bayer AG

I hold shares in:  Roche, BMS, AstraZeneca, Incyte, Teva Pharmaceuticals, Trillium Therapeutics, Compugen, Arrowhead pharmaceuticals, Emergex, QuantumDx and Halozyme Therapeutics

Return to Scientific Advisory Board
Badimon

Lina Badimon

Name
Lina Badimon BSc, PharmD, PhD, FESC, FAHA
Academic Affiliations:
Director of the Cardiovascular Science Program (ICCC) at the Hospital Santa Creu and San Pau, IIB-Sant Pau; CIBER CV. Director of the Cardiovascular Research Chair of the Autonomous University of Barcelona and Director of the UNESCO Chair in Biomedical Sciences Training and Research.
Discipline:
Pharmacology, Cardiovascular Disease
Scientific Interests:
Cardio-metabolic diseases, thrombosis, atherosclerosis and ischemic heart disease
Declaration of Conflicts of Interest:

I received consultant and speakers fees from Amgen, AstraZeneca, Bayer, Lilly and Sanofi.

    Return to Scientific Advisory Board
    Ge

    Junbo Ge

    Name

    Junbo Ge

    Ge Junbo, male, was born in Wulian, Shandong province on Nov. 8, 1962. He is the member of Chinese Academy of Sciences, professor and doctoral supervisor. He received his doctor’s degree of Medicine from German Mayence University in 1993 and now works as the director for Shanghai Institute of Cardiovascular Disease and the Center for Stem Cells and Tissue Engineering, Fudan University. He is also the designate chairman of the Cardiovascular Disease Branch of Chinese Medical Association, council member of the Cardiovascular Angiography and Interventions Association, international consultant of the American Heart Association. In Dec. 2013, he was appointed as the vice president of Tongji University.

    Prof. Ge has been engaged in clinical and scientific research work of cardiovascular disease since 1987, and his research area covers the pathogenesis of coronary heart disease, early diagnosis and treatment plan optimization.

    Return to Scientific Advisory Board
    Langley

    Ruth Langley

    Name
    Ruth Langley PhD, FRCP
    Academic Affiliations:
    Professor of Oncology and Clinical Trials, MRC Programme Leader and Chair of the Cancer Group, MRC Clinical Trials Unit at UCL, honorary consultant in medical oncology at the Brighton and Sussex University Hospital.
    Discipline:
    Medical oncologist; trialist
    Scientific Interests:
    • Aspirin
    • Gastro-oesophageal malignancy
    • Transdermal oestrogen in the treatment of prostate cancer
    • Trials methodology
    Declaration of Conflicts of Interest:
    Has received honorarium from Bayer
    Return to Scientific Advisory Board
    Chan

    Andrew T Chan

    Name
    Andrew T. Chan MD, MPH
    Academic Affiliations:
    Chief, Clinical and Translational Epidemiology Unit, Vice Chair, Division of Gastroenterology, Massachusetts General Hospital, Boston, Co-leader, Cancer Epidemiology Program, Dana-Farber/Harvard Cancer Center, Boston.
    Discipline:
    Gastroenterology
    Scientific Interests:
    • The role of aspirin in the prevention of colorectal cancer and other cancers
    • The role of the gut microbiome in colorectal cancer and other chronic gastrointestinal diseases, including inflammatory bowel disease and diverticulitis
    • The role of diet and lifestyle in colorectal cancer and other chronic gastrointestinal cancers
    Declaration of Conflicts of Interest:

    AACR Honors Dr. Andrew T. Chan With 2019 AACR-Waun Ki Hong Award

    Click here to find the press release.

    I received consultant Bayer and Pfizer, Inc.

    I received grant support for investigator-initiated research from:

    • National Institutes of Health
    • National Cancer Institute
    • Crohn’s and Colitis Foundation
    • Bayer AG
    Return to Scientific Advisory Board
    Gaziano

    Mike Gaziano

    Name
    J Michael Gaziano MD, MPH
    Academic Affiliations:

    Professor of Medicine, Harvard Medical School; Chief Division of Aging, Brigham and Women’s Hospital; Director of Preventive Cardiology and Director of Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System.
    Discipline: Cardiology and Epidemiology

    Scientific Interests:
    I am a chronic disease epidemiologist with a particular interest in the roles that individual lifestyle choices (diet, exercise, smoking), metabolic factors (obesity, high cholesterol, and hypertension), and biochemical and genetic markers play on the risk of cardiovascular disease and other chronic illnesses. Also, of interest is the impact that vascular disease has on other organ systems, including cognitive dysfunction and renal disease. I have an interest in the design of large-scale trials and observational studies nested in large health care systems using big data analytic techniques.
    Declaration of Conflicts of Interest:

    I received consultant and speaker fees Bayer.

    I received grant support as a principal investigator or co-investigator for research from the VA, DOD, NIH, Merck and Kowa.

    Return to Scientific Advisory Board
    Pierre A Web Photo

    Pierre Amarenco

    Name

    Pierre Amarenco, MD, FAHA, FAAN

    Academic Affiliations:
    • Professor of Neurology at Paris-Diderot Sorbonne University 
    • Chairman of the Department of Neurology and Stroke Center; Bichat University Hospital
    • Co-Director INSERM Unit-698 “Clinical Research in Atherothrombosis”
    Discipline:

    Neurology and Vascular Neurology

    Scientific Interests:
    • Understanding and preventing stroke and vascular diseases
    • Clinical trials in prevention of vascular diseases
    • Carotid intima-media thickness studies
    • Lipid trials: prevention and therapeutic –protective- evaluation
    Declaration of Conflicts of Interest:

    N/A

    Return to Scientific Advisory Board
    CarloPatrono

    Carlo Patrono

    CHAIR
    Name
    Carlo Patrono MD, FESC, FRCP
    Academic Affiliations:
    Adjunct Professor of Pharmacology at the Catholic University School of Medicine in Rome (Italy) and at the Perelman School of Medicine of the University of Pennsylvania in Philadelphia (USA).
    Discipline:
    Clinical Pharmacology
    Scientific Interests:
    • Studying platelet activation and inhibition in diabetes mellitus
    • Studying platelet activation and inhibition in myeloproliferative neoplasms
    • Investigating the mechanism of action of low-dose aspirin in preventing colorectal cancer
    Declaration of Conflicts of Interest:

    I received consultant and speakers fees from Acticor Biotech,  Amgen,  Bayer, GlaxoSmithKline,  Tremeau,  Zambon.

    I received grant support for investigator-initiated research from:

    • AIFA (Italian Drug Agency)
    • Bayer AG
    • Cancer Research UK
    • European Commission, FP6 and FP7 Programmes

      Return to Scientific Advisory Board

      Have something to say about aspirin?

      We would like to hear from you and have a chat, and maybe feature you on our podcast. Please fill in the form below and we will contact you with further information.

      This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.